PTPN22 and neoplasm: However, CREKA-labeled Abraxane did not cause a highly significant inhibition in tumor volume compared to that of untargeted Abraxane, suggesting a superior efficiency in delivering Abraxane into tumors using LyP-1 as a targeting ligand instead of CREKA (Karmali et al., 2009).